Filing Overview
On May 10, 2021, GX Acquisition Corp. (the SPAC and registrant) filed a Form 8-K under Item 8.01 regarding its proposed business combination with Celularity Inc., an allogeneic cellular therapy company. The filing does not contain quarterly or annual operating results for Celularity.
Business Context and Reporting Period
GX reaffirmed its support for an amendment extending the deadline to complete its initial business combination from May 23, 2021 to July 31, 2021. Stockholders were scheduled to vote on the extension at a special meeting on May 14, 2021.
GX and Celularity were continuing to address SEC staff comments on the proxy statement/prospectus and satisfy closing conditions for the proposed Celularity Business Combination.
Financial and Capital Markets Terms
- The trust-account balance attributable to each public share was approximately $10.15 as of the March 23, 2021 record date.
- If the extension were approved, GX agreed to contribute $0.025 per share for each month of the extension, subject to partial-month proration, with a maximum aggregate contribution of $0.0565 per non-redeemed public share.
- The planned deposits were $0.0315 per share on or before May 23, 2021 and $0.025 per share on or before July 1, 2021.
- No deposits would be made if the extension proposal were not approved or after completion of the Celularity Business Combination.
- Affiliates of GX Sponsor LLC agreed to fund the contributions as a non-interest-bearing loan. The loan would be repayable upon completion of the business combination in cash or private placement warrants priced at $1.00 per warrant, with warrant repayment capped at $1.5 million, at the lender’s option.
- Public stockholders voting against the extension could elect to redeem their Class A common stock for their pro rata portion of the trust account, including applicable interest, subject to the terms described in the proxy statement.
- The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures for Celularity or GX beyond the trust-account and contribution amounts described above.
Material Changes Versus Prior Information
The material update was the disclosed maximum trust-account contribution of $0.0565 per non-redeemed public share in connection with the proposed extension. The filing also confirmed that the proposed business combination remained subject to SEC review, stockholder approval, and other closing conditions.
Outlook, Risks, and Unusual Items
- Completion of the business combination was not assured and depended on approval of the extension and business combination proposals, SEC review, and satisfaction of other closing conditions.
- Risks identified include failure to complete the transaction or PIPE investment, insufficient future funding, delays or failures in cellular-therapy research and clinical trials, inability to obtain regulatory approvals, manufacturing scale-up challenges, intellectual-property issues, competition, COVID-19 impacts, litigation, and changes in Celularity’s business plans and projected financial performance.
- The proposed sponsor-affiliate loan and potential repayment through private placement warrants represent unusual transaction-related financing arrangements.
- The filing incorporates forward-looking statements and cautions that actual results may differ materially from expectations.
Key Facts for Investors to Verify
- Whether stockholders approved the extension at the May 14, 2021 special meeting.
- Whether the Celularity Business Combination was ultimately completed and on what revised terms.
- The number of shares redeemed and the resulting trust-account balance and per-share redemption amount.
- Whether the maximum $0.0565 per-share contribution was fully funded and how the sponsor-affiliate loan was repaid.
- The final SEC-approved proxy statement/prospectus, PIPE financing status, and all remaining transaction closing conditions.
- Celularity’s actual financial condition, cash runway, operating losses, clinical-development progress, regulatory status, and funding requirements, which are not provided in this filing.